Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

Keyphrases

• Network Meta-analysis 100%
• Second-line Therapy 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Docetaxel 100%
• Nintedanib 100%
• Second-line Treatment 30%
• Histology 20%
• Overall Survival 20%
• Progression-free Survival 20%
• Adenocarcinoma 20%
• Clinical Benefit 20%
• Erlotinib 20%
• Relative Efficacy 10%
• Monotherapy 10%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 10%
• Lung 10%
• Pemetrexed 10%
• Pivotal Trial 10%
• Best Medical Treatment 10%
• Overall Survival Benefit 10%
• Second-line Agents 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Docetaxel 100%
• Nintedanib 100%
• Overall Survival 30%
• Adenocarcinoma 20%
• Progression Free Survival 20%
• Erlotinib 20%
• Monotherapy 10%
• Pemetrexed 10%